Sindrom Wiskott-Aldrich (SWA) - Sebuah Rare Disease
DOI:
https://doi.org/10.55175/cdk.v47i7.597Kata Kunci:
Imunodefisiensi primer, penyakit langka, sindrom Wiskott-AldrichAbstrak
Sindrom Wiskott-Aldrich (SWA) merupakan kelainan imunodefisiensi primer langka terkait kromosom-X, ditandai dengan trias eksema, trombositopenia, infeksi berat, dan rekuren. Spektrum gangguan ini mulai dari gejala ringan trombositopenia terisolasi hingga presentasi klinis full-blown dengan perdarahan, imunodefisiensi, atopi, autoimunitas, dan keganasan yang mengancam nyawa. Kemajuan transplantasi sel punca hematopoeitik dan terapi gen saat ini memberi harapan untuk mengganti sistem limfohematopoeitik yang mengalami defek.
Wiskott-Aldrich syndrome (WAS) is a rare primary X-linked immunodeficiency disorder characterized by eczema, thrombocytopenia, severe, and recurrent infections. The spectrum of these disorders includes mild symptoms with isolated thrombocytopenia to full-blown life-threatening presentation with bleeding, immunodeficiency, atopy, autoimmunity, and malignancies. Hematopoeitic stem cell transplantation and gene therapy now offers hope to replace the defective lymphohematopoeitic system.
Unduhan
Referensi
Worth A, Thrasher A. Current and emerging treatment options for Wiskott–Aldrich syndrome. Expert Review of Clinical Immunology. 2015;11(9):1015-32.
Candotti F. Clinical manifestations and pathophysiological mechanisms of the Wiskott-Aldrich syndrome. Journal of Clinical Immunology. 2017;38(1):13-27.
Massaad M, Ramesh N, Geha R. Wiskott-Aldrich syndrome: A comprehensive review. Annals of the New York Academy of Sciences. 2013;1285(1):26-43.
Boztug K, Schmidt M, Schwarzer A, Banerjee P, Díez I, Dewey R, et al. Stem-cell gene therapy for the Wiskott–Aldrich syndrome. New England Journal of Medicine. 2010;363(20):1918-27.
Ochs H, Filipovich A, Veys P, Cowan M, Kapoor N. Wiskott-Aldrich syndrome: Diagnosis, clinical and laboratory manifestations, and treatment. Biology of Blood and Marrow Transplantation. 2009;15(1):84-90.
Buchbinder D, Nugent D, Fillipovich A. Wiskott-Aldrich syndrome: Diagnosis, current management, and emerging treatments. The Application of Clinical Genetics. 2014;7:55-66.
Kariya S, Nishizaki K, Paparella M, Cureoglu S. Temporal bone histopathology case of the month Wiskott-Aldrich syndrome. Otology & Neurotology. 2013;34:1-2.
Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A mutliinsti¬tutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994;125(6 Pt 1):876–85.
Kaneko R, Yamamoto S, Okamoto N, Akiyama K, Matsuno R, Toyama D, et al. Wiskott–Aldrich syndrome that was initially diagnosed as immune thrombocytopenic purpura secondary to a cytomegalovirus infection. SAGE Open Medical Case Reports. 2018;6.
Gerrits AJ, Leven EA, Frelinger AL III, Brigstocke SL, Berny-Lang MA, Mitchell WB, et al. Effects of eltrombopag on platelet count and platelet activation in WiskottAldrich syndrome/X linked thrombocytopenia. Blood. 2015;126(11):1367–78.
Jyonouchi S, Gwafila B, Gwalani LA, Ahmad M, Moertel C, Holbert C, et al. Phase I trial of low-dose interleukin 2 therapy in patients with Wiskott-Aldrich syndrome. Clinical Immunology. 2017;179:47–53.
Moratto D, Giliani S, Bonfim C, Mazzolari E, Fischer A, Ochs HD, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: An international collaborative study. Blood. 2011;118(6):1675–84.
Friedrich W, Schutz C, Schulz A, Benninghoff U, Honig M. Results and long-term outcome in 39 patients with Wiskott-Aldrich syndrome transplanted from HLAmatched and -mismatched donors. Immunol Res. 2009;44(1–3):18–24.
Shin CR, Kim MO, Li D, Bleesing JJ, Harris R, Mehta P, et al. Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome. Bone Marrow Transplant. 2012;47(11):1428–35.
Kharya G, Nademi Z, Leahy TR, Dunn J, Barge D, SchulzA, et al. Haploidentical T-cell alpha beta receptor and CD19-depleted stem cell transplant for Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2014;134(5):1199–201.
Oshima K, Imai K, Albert MH, Bittner TC, Strauss G, Filipovich AH, et al. Hematopoietic stem cell transplantation for X-linked thrombocytopenia with mutations in the WAS gene. J Clin Immunol. 2015;35(1):15–21.
Dupre L, Trifari S, Follenzi A, Marangoni F, Lain de Lera T, Bernad A, et al. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Mol Ther 2004;10(5):903–15.
Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013;341:6148.
Ferrua F, Cicalese MP, Galimberti S, Scaramuzza S, Giannelli S, Pajno R, et al. Safety and clinical benefit of lentiviral hematopoietic stem cell gene therapy for WiskottAldrich syndrome. Blood. 2015;126(23):3.
Hacein-Bey Abina S, Gaspar HB, Blondeau J, Caccavelli L, Charrier S, Buckland K, et al. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA. 2015;313(15):1550–63.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2020 https://creativecommons.org/licenses/by-nc/4.0/
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
